CD155 Expression in Acute Myeloid Leukemia

NCT06369662 | Completed

• 2 other identifiers: SECI-CD155SECI-IRB-IORG0006563-545
• Study Type: observational
• Target: 93
• Locations: 1 country
• Sites: 1

Brief Summary

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy. It is the most common form of acute leukemia among adults. In the United States, an estimated 19,940 people will be diagnosed with AML in 2020. CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma, as it correlated with tumor migration, development of metastases, tissue and lymph node invasion, relapse, and poorer survival.

Conditions

Neoplasms; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute

Keywords

CD155; AML; Survival

Outcome Measures

Primary Outcomes (1)

• CD155 expression in AML

  Study the CD155 expression by flow cytometry

  2 years

Secondary Outcomes (2)

• CD155 expression with patients' clinical data

  2 years

• CD155 expression and survival

  2 years

Study Arms (1)

AML Patients

Adult patients (from 18 - 60 years) diagnosed as AML

Diagnostic Test: Flow cytometric immunophenotyping; Diagnostic Test: Complete blood count; Diagnostic Test: Bone marrow aspiration; Diagnostic Test: Cytogenetic testing; Diagnostic Test: FLT3-ITD using High resolution melting curve (HRM) analysis

Interventions

Flow cytometric immunophenotyping DIAGNOSTIC_TEST

CD155 expression by flow cytometric immunophenotyping

AML Patients

Complete blood count DIAGNOSTIC_TEST

Complete blood count with peripheral blood smear examination

AML Patients

Bone marrow aspiration DIAGNOSTIC_TEST

Bone marrow aspiration at both diagnosis and follow up of patients

AML Patients

Cytogenetic testing DIAGNOSTIC_TEST

Karyotyping or AML fluorescence in situ hybridization (FISH) panel for diagnosis and risk stratification of AML patients

AML Patients

FLT3-ITD using High resolution melting curve (HRM) analysis DIAGNOSTIC_TEST

Detection of FLT3-ITD mutation in AML patinets

AML Patients

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients (18 - 60 years old) diagnosed as AML

You may qualify if:

• Patients with newly diagnosed AML.
• Age group: patients more than 18 years old and less than 60 years.
• Patients receiving induction chemotherapy 3\&7 at South Egypt Cancer Institute.

You may not qualify if:

• Patients less than 18 years old and over 60 years.
• Patients with concurrent malignancy.
• Secondary AML.
• Acute Promyelocytic leukemia (AML-M3).

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

South Egypt Cancer Institute, Assiut University

Asyut, 71111, Egypt

Location

Related Publications (8)

• Dougall WC, Kurtulus S, Smyth MJ, Anderson AC. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518.

  PMID: 28258695 BACKGROUND

• Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 2017 Oct;108(10):1934-1938. doi: 10.1111/cas.13324. Epub 2017 Aug 18.

  PMID: 28730595 BACKGROUND

• Gorvel L, Olive D. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies. F1000Res. 2020 May 13;9:F1000 Faculty Rev-354. doi: 10.12688/f1000research.22877.1. eCollection 2020.

  PMID: 32489646 BACKGROUND

• Li XY, Das I, Lepletier A, Addala V, Bald T, Stannard K, Barkauskas D, Liu J, Aguilera AR, Takeda K, Braun M, Nakamura K, Jacquelin S, Lane SW, Teng MW, Dougall WC, Smyth MJ. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest. 2018 Jun 1;128(6):2613-2625. doi: 10.1172/JCI98769. Epub 2018 May 14.

  PMID: 29757192 BACKGROUND

• Liu L, Chang YJ, Xu LP, Zhang XH, Wang Y, Liu KY, Huang XJ. T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clin Immunol. 2018 May;190:32-40. doi: 10.1016/j.clim.2018.02.009. Epub 2018 Mar 15.

  PMID: 29477343 BACKGROUND

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.

  PMID: 31912902 BACKGROUND

• Zhang H, Yang Z, Du G, Cao L, Tan B. CD155-Prognostic and Immunotherapeutic Implications Based on Multiple Analyses of Databases Across 33 Human Cancers. Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033820980088. doi: 10.1177/1533033820980088.

  PMID: 33576304 BACKGROUND

• Bakhshaei P, Kazemi MH, Golara M, Abdolmaleki S, Khosravi-Eghbal R, Khoshnoodi J, Judaki MA, Salimi V, Douraghi M, Jeddi-Tehrani M, Shokri F. Investigation of the Cellular Immune Response to Recombinant Fragments of Filamentous Hemagglutinin and Pertactin of Bordetella pertussis in BALB/c Mice. J Interferon Cytokine Res. 2018 Apr;38(4):161-170. doi: 10.1089/jir.2017.0060.

  PMID: 29638208 RESULT

Biospecimen

Retention: SAMPLES WITH DNA

Peripheral blood or Bone marrow aspiration specimens

MeSH Terms

Conditions

Neoplasms; Hematologic Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute

Interventions

Blood Cell Count

Condition Hierarchy (Ancestors)

Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases; Neoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Cell Count; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Hematologic Tests; Investigative Techniques; Cell Physiological Phenomena; Blood Physiological Phenomena; Circulatory and Respiratory Physiological Phenomena

Study Officials

• Nehal Rayan, M.D.

  Assistant Lecturer

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer

Study Record Dates

• First Submitted: July 12, 2021
• First Posted: April 17, 2024
• Study Start: July 1, 2022
• Primary Completion: December 31, 2023
• Study Completion: May 31, 2024
• Last Updated: October 16, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)